nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—KDR—age related macular degeneration	0.786	1	CbGaD
Regorafenib—Sorafenib—KDR—age related macular degeneration	0.00508	1	CrCbGaD
Regorafenib—DDR2—eye—age related macular degeneration	0.00377	0.0777	CbGeAlD
Regorafenib—DDR2—retina—age related macular degeneration	0.00374	0.077	CbGeAlD
Regorafenib—DDR2—connective tissue—age related macular degeneration	0.00363	0.0749	CbGeAlD
Regorafenib—EPHX2—eye—age related macular degeneration	0.00255	0.0525	CbGeAlD
Regorafenib—EPHX2—retina—age related macular degeneration	0.00252	0.052	CbGeAlD
Regorafenib—FLT4—eye—age related macular degeneration	0.0023	0.0473	CbGeAlD
Regorafenib—RET—connective tissue—age related macular degeneration	0.00195	0.0403	CbGeAlD
Regorafenib—FGFR2—eye—age related macular degeneration	0.00193	0.0397	CbGeAlD
Regorafenib—FGFR2—connective tissue—age related macular degeneration	0.00186	0.0383	CbGeAlD
Regorafenib—FLT1—eye—age related macular degeneration	0.00179	0.0368	CbGeAlD
Regorafenib—TEK—connective tissue—age related macular degeneration	0.00178	0.0367	CbGeAlD
Regorafenib—RAF1—eye—age related macular degeneration	0.00178	0.0366	CbGeAlD
Regorafenib—FLT1—retina—age related macular degeneration	0.00177	0.0365	CbGeAlD
Regorafenib—FLT1—connective tissue—age related macular degeneration	0.00172	0.0355	CbGeAlD
Regorafenib—RAF1—connective tissue—age related macular degeneration	0.00171	0.0353	CbGeAlD
Regorafenib—PDGFRA—connective tissue—age related macular degeneration	0.00161	0.0332	CbGeAlD
Regorafenib—KDR—eye—age related macular degeneration	0.00151	0.0311	CbGeAlD
Regorafenib—KDR—retina—age related macular degeneration	0.0015	0.0308	CbGeAlD
Regorafenib—KDR—connective tissue—age related macular degeneration	0.00145	0.03	CbGeAlD
Regorafenib—PDGFRB—eye—age related macular degeneration	0.00131	0.0269	CbGeAlD
Regorafenib—KIT—connective tissue—age related macular degeneration	0.00129	0.0266	CbGeAlD
Regorafenib—PDGFRB—connective tissue—age related macular degeneration	0.00126	0.0259	CbGeAlD
Regorafenib—ABL1—eye—age related macular degeneration	0.00116	0.024	CbGeAlD
Regorafenib—ABL1—retina—age related macular degeneration	0.00115	0.0238	CbGeAlD
Regorafenib—ABL1—connective tissue—age related macular degeneration	0.00112	0.0231	CbGeAlD
Regorafenib—ABCB1—retina—age related macular degeneration	0.000359	0.0074	CbGeAlD
Regorafenib—KIT—Adaptive Immune System—C3—age related macular degeneration	4.43e-05	0.000276	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD36—age related macular degeneration	4.42e-05	0.000276	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—CRP—age related macular degeneration	4.39e-05	0.000273	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TGFBR1—age related macular degeneration	4.38e-05	0.000273	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—C3—age related macular degeneration	4.38e-05	0.000273	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—C3—age related macular degeneration	4.37e-05	0.000272	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NMNAT1—age related macular degeneration	4.31e-05	0.000269	CbGpPWpGaD
Regorafenib—KIT—Disease—TGFBR1—age related macular degeneration	4.31e-05	0.000268	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—SQSTM1—age related macular degeneration	4.31e-05	0.000268	CbGpPWpGaD
Regorafenib—RAF1—Focal Adhesion—VEGFA—age related macular degeneration	4.28e-05	0.000267	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—TLR4—age related macular degeneration	4.28e-05	0.000267	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	4.27e-05	0.000266	CbGpPWpGaD
Regorafenib—KIT—Immune System—SQSTM1—age related macular degeneration	4.23e-05	0.000263	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—TLR4—age related macular degeneration	4.21e-05	0.000262	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—C3—age related macular degeneration	4.2e-05	0.000262	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—APOE—age related macular degeneration	4.2e-05	0.000262	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—C3—age related macular degeneration	4.19e-05	0.000261	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—CD36—age related macular degeneration	4.19e-05	0.000261	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—CRP—age related macular degeneration	4.16e-05	0.000259	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—CRP—age related macular degeneration	4.15e-05	0.000259	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CD36—age related macular degeneration	4.15e-05	0.000259	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TGFBR1—age related macular degeneration	4.12e-05	0.000256	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KDR—age related macular degeneration	4.12e-05	0.000256	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—CD36—age related macular degeneration	4.11e-05	0.000256	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CST3—age related macular degeneration	4.09e-05	0.000255	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TGFBR1—age related macular degeneration	4.09e-05	0.000255	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RHO—age related macular degeneration	4.08e-05	0.000254	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—VEGFA—age related macular degeneration	4.08e-05	0.000254	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TGFBR1—age related macular degeneration	4.08e-05	0.000254	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CD36—age related macular degeneration	4.04e-05	0.000252	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—SQSTM1—age related macular degeneration	4.01e-05	0.00025	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—SQSTM1—age related macular degeneration	4e-05	0.000249	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—TLR4—age related macular degeneration	3.99e-05	0.000249	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD36—age related macular degeneration	3.99e-05	0.000248	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—TLR4—age related macular degeneration	3.98e-05	0.000248	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—KDR—age related macular degeneration	3.96e-05	0.000247	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—C3—age related macular degeneration	3.93e-05	0.000245	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TGFBR1—age related macular degeneration	3.89e-05	0.000242	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NMNAT1—age related macular degeneration	3.85e-05	0.00024	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	3.85e-05	0.00024	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—C3—age related macular degeneration	3.83e-05	0.000239	CbGpPWpGaD
Regorafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	3.8e-05	0.000236	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—C3—age related macular degeneration	3.78e-05	0.000235	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ELOVL4—age related macular degeneration	3.77e-05	0.000235	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NMNAT1—age related macular degeneration	3.76e-05	0.000234	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CRP—age related macular degeneration	3.74e-05	0.000233	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—SQSTM1—age related macular degeneration	3.73e-05	0.000232	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CD36—age related macular degeneration	3.7e-05	0.00023	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TGFBR1—age related macular degeneration	3.67e-05	0.000229	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CRP—age related macular degeneration	3.65e-05	0.000227	CbGpPWpGaD
Regorafenib—RAF1—Disease—CST3—age related macular degeneration	3.65e-05	0.000227	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—KDR—age related macular degeneration	3.62e-05	0.000225	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—SQSTM1—age related macular degeneration	3.61e-05	0.000225	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—SLC16A8—age related macular degeneration	3.59e-05	0.000224	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—TLR4—age related macular degeneration	3.59e-05	0.000223	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD36—age related macular degeneration	3.55e-05	0.000221	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—CCL2—age related macular degeneration	3.53e-05	0.00022	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—SQSTM1—age related macular degeneration	3.53e-05	0.00022	CbGpPWpGaD
Regorafenib—ABL1—Immune System—SQSTM1—age related macular degeneration	3.51e-05	0.000219	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NMNAT1—age related macular degeneration	3.51e-05	0.000219	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—C3—age related macular degeneration	3.51e-05	0.000218	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—TLR4—age related macular degeneration	3.5e-05	0.000218	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	3.49e-05	0.000218	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—VEGFA—age related macular degeneration	3.49e-05	0.000217	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	3.39e-05	0.000211	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—VEGFA—age related macular degeneration	3.38e-05	0.000211	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	3.37e-05	0.00021	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—C3—age related macular degeneration	3.37e-05	0.00021	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—C3—age related macular degeneration	3.37e-05	0.00021	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ELOVL4—age related macular degeneration	3.36e-05	0.00021	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TGFBR1—age related macular degeneration	3.34e-05	0.000208	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CRP—age related macular degeneration	3.33e-05	0.000208	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TGFBR1—age related macular degeneration	3.31e-05	0.000206	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ELOVL4—age related macular degeneration	3.28e-05	0.000205	CbGpPWpGaD
Regorafenib—RAF1—Disease—TGFBR1—age related macular degeneration	3.27e-05	0.000204	CbGpPWpGaD
Regorafenib—RAF1—Immune System—SQSTM1—age related macular degeneration	3.21e-05	0.0002	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—TLR4—age related macular degeneration	3.2e-05	0.000199	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD36—age related macular degeneration	3.14e-05	0.000196	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—APOE—age related macular degeneration	3.13e-05	0.000195	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	3.12e-05	0.000194	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFBR1—age related macular degeneration	3.07e-05	0.000191	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KDR—age related macular degeneration	3.07e-05	0.000191	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ELOVL4—age related macular degeneration	3.07e-05	0.000191	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—VEGFA—age related macular degeneration	3.06e-05	0.00019	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—SLC16A8—age related macular degeneration	3.04e-05	0.000189	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—SQSTM1—age related macular degeneration	3.03e-05	0.000189	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFBR1—age related macular degeneration	3.02e-05	0.000188	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	3.01e-05	0.000187	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—SQSTM1—age related macular degeneration	3e-05	0.000187	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—C3—age related macular degeneration	2.98e-05	0.000186	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—LIPC—age related macular degeneration	2.95e-05	0.000184	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—LIPC—age related macular degeneration	2.95e-05	0.000184	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—VEGFA—age related macular degeneration	2.91e-05	0.000181	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD36—age related macular degeneration	2.89e-05	0.00018	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFBR1—age related macular degeneration	2.86e-05	0.000178	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFBR1—age related macular degeneration	2.85e-05	0.000178	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CETP—age related macular degeneration	2.85e-05	0.000177	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CETP—age related macular degeneration	2.85e-05	0.000177	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—age related macular degeneration	2.84e-05	0.000177	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD36—age related macular degeneration	2.83e-05	0.000177	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CRP—age related macular degeneration	2.83e-05	0.000177	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—VEGFA—age related macular degeneration	2.79e-05	0.000174	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—CETP—age related macular degeneration	2.79e-05	0.000174	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SQSTM1—age related macular degeneration	2.78e-05	0.000173	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CETP—age related macular degeneration	2.74e-05	0.000171	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—C3—age related macular degeneration	2.74e-05	0.00017	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SQSTM1—age related macular degeneration	2.73e-05	0.00017	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—TLR4—age related macular degeneration	2.72e-05	0.000169	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SLC16A8—age related macular degeneration	2.71e-05	0.000169	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD36—age related macular degeneration	2.69e-05	0.000168	CbGpPWpGaD
Regorafenib—KIT—Immune System—C3—age related macular degeneration	2.69e-05	0.000167	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD36—age related macular degeneration	2.68e-05	0.000167	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC16A8—age related macular degeneration	2.65e-05	0.000165	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CCL2—age related macular degeneration	2.63e-05	0.000164	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CRP—age related macular degeneration	2.6e-05	0.000162	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SQSTM1—age related macular degeneration	2.59e-05	0.000162	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SQSTM1—age related macular degeneration	2.59e-05	0.000161	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFBR1—age related macular degeneration	2.57e-05	0.00016	CbGpPWpGaD
Regorafenib—KIT—Immune System—CRP—age related macular degeneration	2.56e-05	0.000159	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—C3—age related macular degeneration	2.55e-05	0.000159	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—C3—age related macular degeneration	2.54e-05	0.000158	CbGpPWpGaD
Regorafenib—BRAF—Disease—APOE—age related macular degeneration	2.54e-05	0.000158	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—LIPC—age related macular degeneration	2.51e-05	0.000156	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—TLR4—age related macular degeneration	2.49e-05	0.000155	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—VEGFA—age related macular degeneration	2.49e-05	0.000155	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC16A8—age related macular degeneration	2.47e-05	0.000154	CbGpPWpGaD
Regorafenib—KIT—Immune System—TLR4—age related macular degeneration	2.45e-05	0.000153	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CRP—age related macular degeneration	2.43e-05	0.000151	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CRP—age related macular degeneration	2.42e-05	0.000151	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CETP—age related macular degeneration	2.42e-05	0.000151	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD36—age related macular degeneration	2.42e-05	0.000151	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—C3—age related macular degeneration	2.37e-05	0.000148	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD36—age related macular degeneration	2.36e-05	0.000147	CbGpPWpGaD
Regorafenib—FGFR2—Disease—APOE—age related macular degeneration	2.35e-05	0.000146	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SQSTM1—age related macular degeneration	2.33e-05	0.000145	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—TLR4—age related macular degeneration	2.33e-05	0.000145	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—TLR4—age related macular degeneration	2.32e-05	0.000144	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NMNAT1—age related macular degeneration	2.31e-05	0.000144	CbGpPWpGaD
Regorafenib—KIT—Disease—APOE—age related macular degeneration	2.31e-05	0.000144	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFBR1—age related macular degeneration	2.29e-05	0.000143	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—C3—age related macular degeneration	2.29e-05	0.000143	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—VEGFA—age related macular degeneration	2.27e-05	0.000141	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—C3—age related macular degeneration	2.24e-05	0.00014	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—C3—age related macular degeneration	2.23e-05	0.000139	CbGpPWpGaD
Regorafenib—ABL1—Immune System—C3—age related macular degeneration	2.23e-05	0.000139	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—APOE—age related macular degeneration	2.21e-05	0.000137	CbGpPWpGaD
Regorafenib—FGFR1—Disease—APOE—age related macular degeneration	2.19e-05	0.000136	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—APOE—age related macular degeneration	2.19e-05	0.000136	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—VEGFA—age related macular degeneration	2.18e-05	0.000136	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CRP—age related macular degeneration	2.18e-05	0.000136	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KDR—age related macular degeneration	2.16e-05	0.000135	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD36—age related macular degeneration	2.15e-05	0.000134	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—VEGFA—age related macular degeneration	2.14e-05	0.000133	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CRP—age related macular degeneration	2.12e-05	0.000132	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TLR4—age related macular degeneration	2.09e-05	0.00013	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—APOE—age related macular degeneration	2.09e-05	0.00013	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SQSTM1—age related macular degeneration	2.08e-05	0.000129	CbGpPWpGaD
Regorafenib—RAF1—Immune System—C3—age related macular degeneration	2.04e-05	0.000127	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TLR4—age related macular degeneration	2.04e-05	0.000127	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	2.02e-05	0.000126	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ELOVL4—age related macular degeneration	2.02e-05	0.000126	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—age related macular degeneration	2.01e-05	0.000125	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—VEGFA—age related macular degeneration	1.99e-05	0.000124	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—APOE—age related macular degeneration	1.97e-05	0.000123	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—VEGFA—age related macular degeneration	1.96e-05	0.000122	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CRP—age related macular degeneration	1.94e-05	0.000121	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—C3—age related macular degeneration	1.93e-05	0.00012	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—C3—age related macular degeneration	1.91e-05	0.000119	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TLR4—age related macular degeneration	1.86e-05	0.000116	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCL2—age related macular degeneration	1.85e-05	0.000116	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—LIPC—age related macular degeneration	1.84e-05	0.000114	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	1.81e-05	0.000113	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—APOE—age related macular degeneration	1.79e-05	0.000112	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	1.79e-05	0.000111	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—APOE—age related macular degeneration	1.78e-05	0.000111	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CETP—age related macular degeneration	1.77e-05	0.00011	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—C3—age related macular degeneration	1.77e-05	0.00011	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KDR—age related macular degeneration	1.76e-05	0.000109	CbGpPWpGaD
Regorafenib—RAF1—Disease—APOE—age related macular degeneration	1.75e-05	0.000109	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCL2—age related macular degeneration	1.75e-05	0.000109	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CCL2—age related macular degeneration	1.75e-05	0.000109	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KDR—age related macular degeneration	1.74e-05	0.000108	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—C3—age related macular degeneration	1.74e-05	0.000108	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CD36—age related macular degeneration	1.71e-05	0.000107	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CD36—age related macular degeneration	1.71e-05	0.000107	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—age related macular degeneration	1.69e-05	0.000105	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—C3—age related macular degeneration	1.65e-05	0.000103	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CD36—age related macular degeneration	1.65e-05	0.000103	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—APOE—age related macular degeneration	1.65e-05	0.000103	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—C3—age related macular degeneration	1.64e-05	0.000102	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC16A8—age related macular degeneration	1.63e-05	0.000102	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—APOE—age related macular degeneration	1.62e-05	0.000101	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KDR—age related macular degeneration	1.61e-05	0.0001	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	1.59e-05	9.93e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KDR—age related macular degeneration	1.58e-05	9.87e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—LIPC—age related macular degeneration	1.56e-05	9.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—APOE—age related macular degeneration	1.53e-05	9.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—APOE—age related macular degeneration	1.53e-05	9.53e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—APOE—age related macular degeneration	1.51e-05	9.41e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—APOE—age related macular degeneration	1.51e-05	9.41e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCL2—age related macular degeneration	1.51e-05	9.39e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KDR—age related macular degeneration	1.5e-05	9.36e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CETP—age related macular degeneration	1.5e-05	9.35e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KDR—age related macular degeneration	1.5e-05	9.34e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCL2—age related macular degeneration	1.49e-05	9.3e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—C3—age related macular degeneration	1.48e-05	9.22e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—age related macular degeneration	1.45e-05	9.06e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CD36—age related macular degeneration	1.45e-05	9.05e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—LIPC—age related macular degeneration	1.39e-05	8.65e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCL2—age related macular degeneration	1.38e-05	8.62e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—APOE—age related macular degeneration	1.38e-05	8.59e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCL2—age related macular degeneration	1.36e-05	8.46e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—LIPC—age related macular degeneration	1.35e-05	8.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KDR—age related macular degeneration	1.35e-05	8.41e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CETP—age related macular degeneration	1.34e-05	8.34e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—C3—age related macular degeneration	1.32e-05	8.22e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CETP—age related macular degeneration	1.31e-05	8.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL2—age related macular degeneration	1.29e-05	8.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL2—age related macular degeneration	1.29e-05	8.01e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—APOE—age related macular degeneration	1.28e-05	7.98e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—LIPC—age related macular degeneration	1.27e-05	7.88e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—APOE—age related macular degeneration	1.23e-05	7.65e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CETP—age related macular degeneration	1.22e-05	7.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KDR—age related macular degeneration	1.2e-05	7.5e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—age related macular degeneration	1.19e-05	7.42e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL2—age related macular degeneration	1.16e-05	7.22e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—age related macular degeneration	1.13e-05	7.01e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CD36—age related macular degeneration	1.07e-05	6.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL2—age related macular degeneration	1.03e-05	6.43e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—age related macular degeneration	9.68e-06	6.03e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—age related macular degeneration	9.59e-06	5.97e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOE—age related macular degeneration	9.4e-06	5.85e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CD36—age related macular degeneration	9.02e-06	5.62e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—age related macular degeneration	8.89e-06	5.53e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—age related macular degeneration	8.73e-06	5.44e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—LIPC—age related macular degeneration	8.35e-06	5.2e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—age related macular degeneration	8.28e-06	5.16e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—age related macular degeneration	8.26e-06	5.15e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CETP—age related macular degeneration	8.05e-06	5.02e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CD36—age related macular degeneration	8.05e-06	5.01e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOE—age related macular degeneration	7.96e-06	4.96e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CD36—age related macular degeneration	7.86e-06	4.89e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—age related macular degeneration	7.44e-06	4.64e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CD36—age related macular degeneration	7.34e-06	4.57e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOE—age related macular degeneration	7.1e-06	4.42e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOE—age related macular degeneration	6.93e-06	4.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—age related macular degeneration	6.63e-06	4.13e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOE—age related macular degeneration	6.47e-06	4.03e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD36—age related macular degeneration	4.84e-06	3.01e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOE—age related macular degeneration	4.27e-06	2.66e-05	CbGpPWpGaD
